SCHEMBL40953

SCHEMBL40953

O=Cc1csc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 1.00
MAPT P10636 3/20 0.53
TDP1 Q9NUW8 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
PKM P14618 1/20 0.53
KDM4C Q9H3R0 1/20 0.53
ERN1 O75460 4/20 0.53
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
PIM1 P11309 1/20 0.47
MAOB P27338 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
AHR P35869 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30076672 1.00 CYP2A6 (1.00) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL7974567 0.96 CYP2A6 (0.92) CYP2A6MAPTTDP1MEN1KMT2A
Lithium Ion SCHEMBL7974563 0.94 CYP2A6 (0.89) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL9618066 0.86 CYP2A6 (0.75) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL22409641 0.80 CYP2A6 (0.67) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL7544372 0.80 CYP2A6 (0.67) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL2476967 0.79 CYP2A6 (0.65) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL15930269 0.78 CYP2A6 (0.64) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL8996553 0.78 CYP2A6 (0.64) CYP2A6MAPTTDP1MEN1KMT2A
SCHEMBL11708827 0.78 CYP2A6 (0.64) CYP2A6MAPTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
US-11999712-B1 2-(benzo[b]thiophen-3-yl)-1-butyl-4,5-diphenyl-1H-imidazole as an anti-inflammatory and anti-microbial compound King Faisal University (SA) 2024-06-04 US claimed
CN-113912583-A Synthetic process of benzothiophene-3-formaldehyde 南京一苇医药科技有限公司 2022-01-11 CN claimed
CN-112551574-A Sulfur-nitrogen doped porous carbon-coated Li4Ti5O12Lithium ion battery cathode material and preparation method thereof 桐乡市鸿信科技合伙企业(有限合伙) 2021-03-26 CN claimed
CN-111606823-A Method for converting aromatic aldehyde into aromatic nitrile by using inorganic ammonium as nitrogen source and promoted by sulfur powder 湘潭大学 2020-09-01 CN claimed
CN-108059205-A For the up-flow adsorptive reactor of orthophosphates in Adsorption waste water 北京益清源环保科技有限公司 2018-05-22 CN claimed
CN-107486140-A Attapulgite adsorbing material for solidifying chromium in river bottom mud and preparation method thereof 北京清水润土环保科技有限公司 2017-12-19 CN claimed
US-9688701-B2 Production and use of zinc amides LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2017-06-27 US claimed
US-20170043196-A1 Fire Extinguishing Composition Comprising Heterocyclic Compounds XI'AN J&R FIRE FIGHTING EQUIPMENT CO., LTD. (CN) 2017-02-16 US claimed
EP-3095485-A1 FIRE EXTINGUISHING COMPOSITION COMPRISING HETEROCYCLIC COMPOUNDS Xi'an J&R Fire Fighting Equipment Co., Ltd. (CN) 2016-11-23 EP claimed
WO-2014172363-A2 COMBRETASTATIN ANALOGS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-10-23 WO claimed
CN-103736236-A Fire extinguishing composition containing heterocyclic compound XI AN JIAN RUI SAFETY EMERGENCY EQUIPMENT LTD LIABILITY COMPANY 2014-04-23 CN claimed
CN-103509009-A 2-substituted-5-phenyl furan compound, and preparation method, pharmaceutical composition and application thereof SHANGHAI INST MATERIA MEDICA 2014-01-15 CN claimed
US-7994335-B2 Electronically tuned ligands for asymmetric hydrogenation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-09 US claimed
US-20100179343-A1 METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-07-15 US claimed
US-20100041898-A1 Electronically Tuned Ligands For Asymmetric Hydrogenation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US claimed
US-20090299074-A1 BENZO[b]THIOPHEN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJIN PHARMA LIMITED (JP) 2009-12-03 US claimed
EP-1947097-A1 BENZOÝb¨THIOPHEN DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF Teijin Pharma Limited (JP) 2008-07-23 EP claimed
WO-2008067218-A1 ELECTRONICALLY TUNED LIGANDS FOR ASYMMETRIC HYDROGENATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-05 WO claimed
US-6316620-B1 AS LIGANDS TO TRANSITION METALS WHICH ARE USED AS CATALYSTS IN SYNTHESIZING ASYMMETRIC COMPOUNDS TO OBTAIN SPECIFIC ENANTIOMERS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-11-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179343-A1 METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE TDO2, AOX1, DAO CYP2A6 2674/4885MAPT 4873/4885TDP1 802/4885
US-11999712-B1 2-(benzo[b]thiophen-3-yl)-1-butyl-4,5-diphenyl-1H-imidazole as an anti-inflammatory and anti-microbial compound IL1B, NFKBIA, IL4 CYP2A6 2249/4885MAPT 1343/4885TDP1 1672/4885
US-20100041898-A1 Electronically Tuned Ligands For Asymmetric Hydrogenation BID, HDHD5, HRH4 CYP2A6 1228/4885MAPT 3572/4885TDP1 4329/4885
US-20090299074-A1 BENZO[b]THIOPHEN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION CMA1, TPSB2, CTRB1 CYP2A6 244/4885MAPT 2088/4885TDP1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.